The objective of this study is to evaluate the pharmacokinetics (PK) and relative bioavailability of emraclidine following single oral administration of different immediate-release (IR) tablet formulations in healthy adult participants.

Inclusion Criteria:

• Body mass index of 18.5 to 32.0 kg/m2, inclusive.
• Total body weight >= 50 kg.

Exclusion Criteria:

• History of suicidal ideation within one year prior to study treatment administration and/or history of suicidal behavior or non-suicidal self-injury within two years prior to study treatment administration as evidenced by any "yes" answer to questions on the Columbia-Suicide Severity Rating Scale (C-SSRS) at the screening visit or upon initial confinement.

• Vital sign measurements, at Screening and Check-in:

  • Systolic blood pressure >= 140 mmHg or < 100 mmHg
  • Diastolic blood pressure >= 90 mmHg or < 60 mmHg
  • Heart rate > 100 bpm or < 50 bpm
  • Orthostatic hypotension, defined as a decrease of >= 20 mmHg in systolic blood pressure upon standing compared with the supine/sitting blood pressure measurement.

• Female participants of childbearing potential